Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
358.7 USD | +2.38% | +1.56% | +19.79% |
Mar. 26 | Stryker Launches Gamma4 Hip Fracture Nailing System in Europe | CI |
Mar. 25 | Activist investor Politan plans second proxy battle at Masimo, WSJ reports | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 36 and 32.3 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.79% | 136B | A- | ||
-6.44% | 11.49B | A- | ||
+15.53% | 10.12B | C | ||
+4.95% | 6.47B | C | ||
+16.61% | 4.58B | B+ | ||
+10.72% | 3.51B | C- | ||
+11.50% | 3.43B | B- | ||
-11.59% | 2.08B | - | - | |
-10.32% | 2B | - | ||
-27.94% | 1.68B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Stryker Corporation - Nyse
- Ratings Stryker Corporation